Institute of Cellular Medicine, Human Nutrition Research Centre, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Danone Nutricia Research, Nutricia Advanced Medical Nutrition, Uppsalalaan 12, Utrecht Science Park, Utrecht, 3584 CT, The Netherlands.
Calcif Tissue Int. 2019 Oct;105(4):383-391. doi: 10.1007/s00223-019-00581-6. Epub 2019 Jul 23.
Alterations in musculoskeletal health with advanced age contribute to sarcopenia and decline in bone mineral density (BMD) and bone strength. This decline may be modifiable via dietary supplementation. To test the hypothesis that a specific oral nutritional supplement can result in improvements in measures of bone health. Participants (n 380) were participants of the PROVIDE study, a 13-week, multicenter, randomized, controlled, double-blind, 2 parallel-group study among non-malnourished older participants (≥ 65 years) with sarcopenia [determined by Short Physical Performance Battery (SPPB; 0-12) scores between 4 and 9, and a low skeletal muscle mass index (SMI; skeletal muscle mass/BW × 100) ≤ 37% in men and ≤ 28% in women using bioelectric impedance analysis] Supplementation of a vitamin D, calcium and leucine-enriched whey protein drink that comprises a full range of micronutrients (active; 2/day) was compared with an iso-caloric control. Serum 25-hydroxyvitamin D [25(OH)D], parathyroid hormone (PTH), biochemical markers of bone formation (osteocalcin; OC, procollagen type 1 amino-terminal propeptide; P1NP) and resorption (carboxy-terminal collagen crosslinks; CTX), insulin like growth factor 1 (IGF-1) and total-body BMD were analysed pre- and post-intervention. Serum 25(OH)D concentrations increased from 51.1 ± 22.9 nmol/L (mean ± SD) to 78.9 ± 21.1 nmol/L in the active group (p < 0.001 vs. control). Serum PTH showed a significant treatment difference (p < 0.001) with a decline in the active group, and increase in the control group. Serum IGF-1 increased in the active group (p < 0.001 vs. control). Serum CTX showed a greater decline in the active group (p = 0.001 vs. control). There were no significant differences in serum OC or P1NP between groups during the intervention. Total body BMD showed a small (0.02 g/cm; ~ 2%) but significant increase in the active group after supplementation (p = 0.033 vs. control). Consuming a vitamin D, calcium and leucine-enriched whey protein supplement for 13 weeks improved 25(OH)D, suppressed PTH and had small but positive effects on BMD, indicative of improved bone health, in sarcopenic non-malnourished older adults.
随着年龄的增长,肌肉骨骼健康的变化会导致肌肉减少症和骨矿物质密度(BMD)以及骨强度的下降。这种下降可以通过饮食补充来改变。为了验证一种特殊的口服营养补充剂可以改善骨骼健康的假设,研究人员对 380 名非营养不良的老年参与者(≥65 岁)进行了一项为期 13 周的、多中心的、随机的、对照的、双盲、2 平行组研究。这些参与者患有肌肉减少症[通过短体物理性能电池(SPPB;评分 4 至 9)确定,低骨骼肌质量指数(SMI;骨骼肌质量/BW×100)男性≤37%,女性≤28%,使用生物电阻抗分析]。补充富含维生素 D、钙和亮氨酸的乳清蛋白饮料,该饮料包含各种微量营养素(活性;每天 2 次),与等热量对照进行比较。分析了血清 25-羟维生素 D[25(OH)D]、甲状旁腺激素(PTH)、骨形成生化标志物(骨钙素;OC,前胶原 1 氨基末端前肽;P1NP)和吸收(羧基末端胶原交联;CTX)、胰岛素样生长因子 1(IGF-1)和全身 BMD 在前和干预后。血清 25(OH)D 浓度从 51.1±22.9nmol/L(平均值±标准差)增加到 78.9±21.1nmol/L,活性组(p<0.001 与对照组相比)。血清 PTH 显示出显著的治疗差异(p<0.001),活性组下降,对照组增加。血清 IGF-1 在活性组中增加(p<0.001 与对照组相比)。活性组血清 CTX 下降更大(p=0.001 与对照组相比)。在干预期间,两组之间的血清 OC 或 P1NP 无显著差异。全身 BMD 在补充后显示出较小的(0.02g/cm;~2%)但显著增加,活性组(p=0.033 与对照组相比)。在 13 周内食用富含维生素 D、钙和亮氨酸的乳清蛋白补充剂可改善 25(OH)D、抑制 PTH,并对 BMD 产生微小但积极的影响,表明骨骼健康状况得到改善,肌肉减少症非营养不良的老年成年人。